Eisai Co Ltd. has announced the launch of Fycompa, indicated for the adjunctive treatment of partial-onset seizures, with or without secondarily generalized seizures, in Jordan, Kingdom of Saudi Arabia and the United Arab Emirates, or UAE. Fycompa (perampanel) is now licensed for adjunctive treatment of partial-onset seizures, with or without secondarily generalised seizures in Jordan, Kingdom of Saudi Arabia and the United Arab Emirates. Additionally, it is indicated in the United Arab Emirates for the adjunctive treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy (IGE) aged 12 years and older. Perampanel was discovered and developed by Eisai and is available in these countries through a partnership with Hikma Pharmaceuticals PLC.